BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30407457)

  • 1. Early discharge of pediatric patients with cancer, fever, and neutropenia with low-risk of systemic infection.
    Gil-Veloz M; Pacheco-Rosas DO; Solórzano-Santos F; Villasís-Keever MA; Betanzos-Cabrera Y; Miranda-Novales G
    Bol Med Hosp Infant Mex; 2018; 75(6):352-357. PubMed ID: 30407457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study.
    Miedema KG; Tissing WJ; Abbink FC; Ball LM; Michiels EM; van Vliet MJ; de Vries WY; Kamps WA; Norbruis OF; Fiocco M; de Groot-Kruseman HA; van de Wetering MD; de Bont ES
    Eur J Cancer; 2016 Jan; 53():16-24. PubMed ID: 26700076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
    Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA.
    Solórzano-Santos F; Quezada-Herrera A; Fuentes-Pacheco Y; Rodríguez-Coello G; Aguirre-Morales CE; Izelo-Flores D; Muñoz-Hernández O; Miranda-Novales MG; Labra-Zamora MG
    Rev Invest Clin; 2019; 71(4):283-290. PubMed ID: 31448789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia.
    Bash RO; Katz JA; Cash JV; Buchanan GR
    Cancer; 1994 Jul; 74(1):189-96. PubMed ID: 8004575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia.
    Hodgson-Viden H; Grundy PE; Robinson JL
    BMC Pediatr; 2005 May; 5(1):10. PubMed ID: 15904510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
    Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
    Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
    Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India.
    Noronha V; Joshi A; Patil VM; Bhosale B; Muddu VK; Banavali S; Kelkar R; Prabhash K
    Indian J Cancer; 2014; 51(4):470-4. PubMed ID: 26842166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].
    Fouyssac F; Salmon A; Mansuy L; Schmitt C; Bordigoni P; Chastagner P
    Med Mal Infect; 2005 Jun; 35(6):357-62. PubMed ID: 15982848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.
    Innes HE; Smith DB; O'Reilly SM; Clark PI; Kelly V; Marshall E
    Br J Cancer; 2003 Jul; 89(1):43-9. PubMed ID: 12838298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR; Durand CR; Beaulac MT; Steinberg M
    Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
    Aamir M; Abrol P; Sharma D; Punia H
    Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
    Mullen CA; Petropoulos D; Roberts WM; Rytting M; Zipf T; Chan KW; Culbert SJ; Danielson M; Jeha SS; Kuttesch JF; Rolston KV
    Cancer; 1999 Jul; 86(1):126-34. PubMed ID: 10391572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.